Mesothelioma is one of the rarest cancers so there are always clinical trials going on to advance research efforts. This session presents on four different clinical trial areas: immune checkpoint blockades, targeted therapies, anti-angiogenesis, and viral and neoantigen therapies.
These sessions are presented by:
Marjorie Zauderer, MD, Westchester Medical Center
Melina Marmarelis, MD, University of Pennsylvania
This is a recording of a session at the 2024 International Symposium on Malignant Mesothelioma. This symposium is made possible by our generous sponsors: Belluck and Fox, LLP; Dean Omar Branham Shirley, LLP; Maune Raichle Hartley French & Mudd, LLC (MRHFM); Merck; The Gori Law Firm; Bristol Myers Squibb; Early Lucarelli Sweeney & Meisenkothen
Find other recorded sessions and more information at www.curemeso.org/symposium
